Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Patrys Limited
ABN	97 123 055 363

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Campbell
Date of last notice	7 August 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Barrabool Biotechnology Pty Ltd <j and="" k<br="">Campbell Family A/C> Dr. Campbell is a beneficiary of the above entity</j>
Date of change	12 October 2020

⁺ See chapter 19 for defined terms.

No. of securities held prior to change	<u>Direct:</u> 39,395 Fully paid ordinary shares
	3,283 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023
	15,000,000 Unlisted options, exercisable at \$0.0072, expiring on 24 November 2021
	10,000,000 Unlisted options, exercisable at \$0.035, expiring on 22 November 2023
	<u>Indirect:</u> 1,188,395 Fully paid ordinary shares
	396,132 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023
Class	Fully paid ordinary shares
	Unlisted options, exercisable at \$0.0072, expiring on 24 November 2021
Number acquired	6,000,000 Fully paid ordinary shares
Number disposed	6,000,000 Unlisted options, exercisable at \$0.0072, expiring on 24 November 2021
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$43,200
No. of securities held after change	<u>Direct:</u> 6,039,395 Fully paid ordinary shares
	3,283 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023
	9,000,000 Unlisted options, exercisable at \$0.0072, expiring on 24 November 2021
	10,000,000 Unlisted options, exercisable at \$0.035, expiring on 22 November 2023
	<u>Indirect:</u> 1,188,395 Fully paid ordinary shares
	396,132 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of unlisted options.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?	
If prior written clearance was provided, on what date was this	N/A
provided?	

⁺ See chapter 19 for defined terms.